Patients with Atypical Femur Fractures Have the Same Mortality as the Background Population - Drug-Channeling Bias, Bisphosphonate Effects, and Public Health Implications

Journal of Bone and Mineral Research

Volumn 31, Issue 3, 2016, Pages 488-490

  Abrahamsen, Bo ^a,b   Prieto Alhambra, Daniel ^c,d  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b HOLBÆK HOSPITAL   (Denmark)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PLACEBO; PROTON PUMP INHIBITOR; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ATYPICAL FEMUR FRACTURE; CLINICAL DECISION MAKING; FEMUR FRACTURE; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FOREARM FRACTURE; FRAGILITY FRACTURE; HEART ARRHYTHMIA; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; LIFE EXPECTANCY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PNEUMONIA; PROGNOSIS; PUBLIC HEALTH; RISK REDUCTION; SPINE FRACTURE; FEMORAL FRACTURES; STATISTICAL BIAS;

BIAS (EPIDEMIOLOGY); BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMORAL FRACTURES; HUMANS; PUBLIC HEALTH;

EID: 84962784412     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2801     Document Type: Note

References (10)

1. Kharazmi M, Hallberg P, Schilcher J, Aspenberg P, Michaelsson K., Mortality after atypical femoral fractures: a cohort study. J Bone Miner Res. 2016; 31: 491-7.
2. Lyles KW, Colon-Emeric CS, Magaziner JS, et al., Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med. 2007; 357: nihpa40967.
3. Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zweittler E., Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study. Osteoporos Int. 2016; 27: 387-96.
4. Bondo L, Eiken P, Abrahamsen B., Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study. Osteoporos Int. 2013; 24: 245-52.
5. Bogdan Y, Tornett P 3rd, Einhorn TA, et al., Healing time and complications in operatively treated atypical femur fractures associated with bisphosphonate use: a multicenter retrospective cohort. J Orthop Trauma. Epub 2015 Dec 19.
6. E. Medin, F. Goude, H.O. Melberg, et al., European regional differences in all-cause mortality and length of stay for patients with hip fracture. Health Econ. 2015; 24 Suppl 2: 53-64.
7. Johnell O, Kanis JA, Oden A, et al., Mortality after osteoporotic fractures. Osteoporos Int. 2004; 15: 38-42.
8. Karampampa K, Ahlbom A, Michaelsson K, Andersson T, Drefahl S, Modig K., Declining incidence trends for hip fractures have not been accompanied by improvements in lifetime risk or post-fracture survival-a nationwide study of the Swedish population 60 years and older. Bone. 2015; 78: 55-61.
9. C. Muschitz, H.W. Thaler, H.P. Dimai, et al., Atypical femoral fractures-ongoing and history of bone-specific therapy, concomitant diseases, medications, and survival J Clin Densitom. Epub 2015 Jun 23.
10. Hernlund E, Svedbom A, Ivergard M, et al., Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013; 8: 136.